| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 88,7 k € | -4.7% | 93,1 k € | +0.9% | 92,3 k € | +137.7% | 38,8 k € | -60.3% | 97,7 k € | -0.8% | 98,4 k € | +133.0% | 42,2 k € | -52.4% | 88,7 k € | +6.8% | 83,0 k € | +17.7% | 70,5 k € | +14.4% | 61,6 k € | |
| EBITDA | 88,7 k € | -4.7% | 93,1 k € | +0.9% | 92,3 k € | +137.7% | 38,8 k € | -60.3% | 97,7 k € | -0.8% | 98,4 k € | +133.0% | 42,2 k € | -52.4% | 88,7 k € | +8.6% | 81,6 k € | +16.4% | 70,1 k € | +14.0% | 61,6 k € | |
| Operating profit | 85,6 k € | -4.9% | 90,0 k € | -0.7% | 90,6 k € | +133.5% | 38,8 k € | -60.3% | 97,7 k € | -0.8% | 98,4 k € | +133.0% | 42,2 k € | -52.4% | 88,7 k € | +9.4% | 81,0 k € | +20.6% | 67,2 k € | +10.2% | 61,0 k € | |
| Profit/loss | 59,3 k € | -0.3% | 59,4 k € | +3.0% | 57,7 k € | +273.0% | 15,5 k € | -73.2% | 57,7 k € | +5.6% | 54,6 k € | +314.3% | 13,2 k € | -68.2% | 41,4 k € | -36.9% | 65,6 k € | +312.2% | 15,9 k € | -29.5% | 22,6 k € | |
| Equity | 455,0 k € | +15.0% | 395,7 k € | +17.7% | 336,3 k € | +20.7% | 278,6 k € | +5.9% | 263,1 k € | +28.1% | 205,4 k € | +36.2% | 150,8 k € | +9.6% | 137,7 k € | +43.0% | 96,3 k € | +214.4% | 30,6 k € | -31.5% | 44,7 k € | |
| Total assets | 1,1 M € | +2.9% | 1,0 M € | +4.0% | 984,4 k € | +1.9% | 966,4 k € | -1.2% | 978,5 k € | +0.5% | 973,8 k € | -2.7% | 1,0 M € | -0.4% | 1,0 M € | +2.9% | 976,7 k € | +1.1% | 965,7 k € | +1.1% | 955,6 k € | |
| Cash | 2,0 k € | -32.3% | 2,9 k € | +4.1% | 2,8 k € | -44.2% | 5,1 k € | +86.4% | 2,7 k € | +93.3% | 1,4 k € | +623.4% | 193,9 € | -73.1% | 720,5 € | -53.8% | 1,6 k € | — | — | |||
| Debts | 597,7 k € | -4.8% | 627,5 k € | -3.2% | 648,1 k € | -5.8% | 687,9 k € | -3.8% | 715,4 k € | -6.9% | 768,4 k € | -9.6% | 850,4 k € | -2.0% | 867,6 k € | -1.5% | 880,5 k € | -5.8% | 934,9 k € | +2.6% | 910,8 k € | |
Private limited company · Nivelles · incorporated on 29/11/2013
Private limited company profitable and well capitalised. Cash position declining (-32.3%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
GROUPE TETE PHARMACEUTICAL is a Private limited company incorporated in 2013. Its main activity is: Manufacture of basic pharmaceutical products. Its registered office is in Nivelles.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette